Arrowhead Pharmaceuticals In

ARWRNASDAQ · US

Holders

REDUCEDT+2
Olukotun Adeoye Y
Arrowhead Pharmaceuticals In · NASDAQ
−2,000 sh · $173.9K
Filed 20 Aug 2026SEC Form 4view source
REDUCEDT+2
Perry Michael S
Arrowhead Pharmaceuticals In · NASDAQ
−11,600 sh · $1.0M
Filed 20 Aug 2026SEC Form 4view source
DISCLOSEDQuarterly
Polen Capital Management
Arrowhead Pharmaceuticals In · NASDAQ
6,612 sh · $538.9K
Filed 30 Jun 2026SEC 13Fview source
DISCLOSEDQuarterly
Renaissance Technologies
Arrowhead Pharmaceuticals In · NASDAQ
1,036,495 sh · $65.0M
Filed 31 Mar 2026SEC 13Fview source
DISCLOSEDQuarterly
Two Sigma Investments
Arrowhead Pharmaceuticals In · NASDAQ
45,700 sh · $2.9M
Filed 31 Mar 2026SEC 13Fview source
DISCLOSEDQuarterly
Bridgewater Associates
Arrowhead Pharmaceuticals In · NASDAQ
95,552 sh · $6.0M
Filed 31 Mar 2026SEC 13Fview source
DISCLOSEDStale
BlackRock
Arrowhead Pharmaceuticals In · NASDAQ
15,683,206 sh · $407.6M
Filed 30 Jun 2024SEC 13Fview source